Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Nintedanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.52 |
| ▸ | FGFR1 known ✓ | P11362 | 4/20 | 0.52 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.52 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.52 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.52 |
| ▸ | FGFR2 known ✓ | P21802 | 2/20 | 0.52 |
| ▸ | FGFR4 known ✓ | P22455 | 2/20 | 0.52 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.52 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.52 |
| ▸ | MELK | Q14680 | 9/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nintedanib SCHEMBL431006 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL29352914 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL1535871 | 1.00 | AAK1 (0.59) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2365685 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2365677 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL4262457 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2366107 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2376199 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2376201 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA | |
| Nintedanib SCHEMBL2366115 | 0.99 | AAK1 (0.58) | AAK1PDGFRBFGFR1KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533313-B2 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | INSPIRMED CORP. (TW) | 2026-01-27 | — | — | US | claimed |
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | claimed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | claimed |
| EP-2313087-B2 | PHARMACEUTICAL DOSAGE FORM FOR IMMEDIATE RELEASE OF AN INDOLINONE DERIVATIVE | BOEHRINGER INGELHEIM INT (DE) | 2023-11-22 | — | — | EP | claimed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | claimed |
| US-20230088661-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP (TW) | 2023-03-23 | — | — | US | claimed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | claimed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | claimed |
| EP-2878297-B1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INT (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190160054-A1 | PHARMACEUTICAL COMBINATION OF NINTEDANIB, TRIFLURIDINE AND TIPIRACIL FOR TREATING COLORECTAL CANCER | BOEHRINGER INGELHEIM INT (DE) | 2019-05-30 | — | — | US | claimed |
| JP-2006524634-A | — | — | 2006-11-02 | — | — | JP | claimed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | claimed |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| WO-2006018182-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| EP-1473043-A1 | Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-03 | — | — | EP | claimed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533313-B2 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | ADRM1, ALK, AGK | PDGFRB 269/4885FGFR1 2109/4885KDR 729/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | PDGFRB 1449/4885FGFR1 398/4885KDR 4496/4885 |
| US-20190160054-A1 | PHARMACEUTICAL COMBINATION OF NINTEDANIB, TRIFLURIDINE AND TIPIRACIL FOR TREATING COLORECTAL CANCER | NUDT15, NUDT1, SLC28A1 | PDGFRB 648/4885FGFR1 159/4885KDR 296/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | PDGFRB 1449/4885FGFR1 398/4885KDR 4496/4885 |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | PDGFRB 40/4885FGFR1 749/4885KDR 971/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | PDGFRB 796/4885FGFR1 460/4885KDR 3915/4885 |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | CCNA1, MKI67, CCNA2 | PDGFRB 687/4885FGFR1 227/4885KDR 1002/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | PDGFRB 117/4885FGFR1 378/4885KDR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.